SFRP1 and breast carcinoma: For this, we induced EMT in BT474 (HER2-high breast cancer cells) by treating the cells with an EMT-inducing supplement cocktail (containing Wnt-5a, TGF-β1, anti-human E-Cadherin antibody, anti-human sFRP1 antibody, and anti-human Dkk1 antibody) for 15 days.